Nautilus Biotechnology Inc reports results for the quarter ended in January 1 - Earnings Summary

Nautilus Biotechnology

29/10/2024 14:19

* Nautilus Biotechnology Inc  NAUT.OQ  reported a quarterly
adjusted loss of 13 cents​​ per share for the quarter ended
January 1, identical to the same quarter last year.  The mean
expectation of five analysts for the quarter was for a loss
of 16 cents per share. Wall Street expected results to range
from -18 cents to -15 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Nautilus Biotechnology Inc's reported EPS for the quarter
was a
loss of 13 cents​.
    * The company reported a quarterly loss of $16.45 million.
    * Nautilus Biotechnology Inc shares had fallen by 1.4% this
quarter and lost 6.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Nautilus
Biotechnology Inc is 4.00 
This summary was machine generated from LSEG data October 29 at
02:18 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 1 0001       -0.16          -0.13          Beat
 Jun. 30 2024      -0.16          -0.14          Beat
 Mar. 31 2024      -0.16          -0.15          Beat
 Dec. 31 2023      -0.14          -0.14          Met